Drafting Perfect 483 Responses: The New FDA Guidelines Explained. FDA Form 483 observations are issued when investigators identify conditions that may violate cGMP requirements.
How to Maximize Compliance in 2026 with AI-Assisted APQR Products. Discover how to leverage low-code apps for data integrity in the 2026 Compliance Revolution and enhance your APQR process to take advantage of AI-Assisted Products.
Tagged : AI, APQR, Biopharma, Biopharmaceutical, Compliance, Digital Transformation, GxP, Pharma 4.0, quality, Quality 4.0
The pharmaceutical industry stands at a crossroads where regulatory expectations continue to evolve, patient safety remains paramount, and competitive pressures demand operational excellence. In this complex landscape, organizations …
The Raw Material Risks You Can’t Afford to Ignore: Ignoring raw material risks like unpredictable supply chains, political upheaval, or dwindling resource can seriously disrupt production, drive up costs, and weaken a company’s ability to bounce back.
Pharmacovigilance, the science, and activities related to detecting, assessing, understanding, and preventing adverse effects or other drug-related problems, is critical in patient safety.